Collabrity’s Fundraising Solutions for Biotechs
C-level Leadership Applied to Capital Raises
- Our focus is on serving therapeutic biotechnology companies worldwide who seek to raise less than $75 million through private placement financing rounds – who we believe are underserved.
- We train and deploy Associates cost-effectively, passing savings on to clients and enabling the broad investor coverage that a global fundraising campaign requires.
- As a result, Collabrity C-Level Executives are free to focus their efforts on the highest, best use of their strategic insights, experience, and skills.
- We also provide seasoned CFO leadership to position you for the re-opened biotech IPO market and run the IPO process from start to finish.
Senior Management Teams with CFO’s are More Likely to Get Financed
Many CEO’s and investors prefer our:
- Trusted Relationships with Investors – No VC on your Board? No problem. Collabrity has a reputation for introducing only high-quality therapeutic biotech companies matched to the interests and strategies of investors. We provide warm introductions to a current, worldwide network of institutional, family office, and high-net-worth investors.
- Quality – a CFO with decades of broad therapeutic biotechnology experience who runs the financing from start to finish
- Global Reach – empowered by Associates and proprietary technology, at lower cost, more hours on campaign, more comprehensive outreach to qualified investors around the world, and not a search restricted to only one individual’s network or one firm’s network
- Continuity – an executive team member potentially continuing post-financing, and not a temporary transactional broker
C-Level Executives Empowered by Staff and Resources
100+ hours per month of support from:
- Chief Financial / Executive Officers
- Collabrity Associates
- Global Database – comprehensive, proprietary investor database customized for your needs
- drawing on our large investor therapeutic biotechnology database, a curated online CRM database that you keep would be composed of global investors who are qualified as prospective investors in your company and would be made available at no additional cost
- rapid biotech investor matching to each client enabled by proprietary software tools – AnNie Qi™ by Collabrity
- Flexibility – because we are licensed, to reduce your current cash burn Collabrity offers commission compensation and equity options
AnNie Qi™ – Precision Financing for the Precision Medicine Era
Try it out at AnNie QiTM
- Using a small extract of our much larger database (only institutional investors whose names begin with the letter “A”) and created using our proprietary Artificial Intelligence / Natural Intelligence technology for Qualifying Investment or AnNie Qi™, this site demonstrates the powerful tools Collabrity brings to supporting early-stage therapeutic biotechnology company CEOs and investors.
The Collabrity Report
Daily summary of financings for therapeutic biotechnology company executives and investors
- I found it challenging to get news about biopharma acquisitions and financings.
- So, I created a free custom site called the Collabrity Report that delivers the past two weeks of concise therapeutic biotech financing headlines all in one place, and is:
- refreshed by the Collabrity team several times each business day
- linked to dozens of global biopharma news organizations
- available in 20 languages
- laser-focused
- Collabrity Report is now the most comprehensive free online resource for current biotech financings worldwide.
Highly-Qualified CFO Support from Collabrity
- Our engagement model is designed to lead to long-term equivalence of the full-time CFO support your company needs – a fully integrated member of your team who has been there for you from the start
- Christopher Lehman’s 30-year career in biotechnology spans business development and financial leadership roles encompassing all aspects of a CFOs responsibilities
- Leadership roles in therapeutics, diagnostics, CRO, and industrial biotech
- 40 partnering and financing transactions totaling over $1.9 Billion
- Broad investor network of early and late-stage institutional investors
- Collabrity facilitates the placement of C-Level Executives with exceptional skills and experience to co-lead our expanding number of client engagements
© , all rights reserved
Contact Christopher Lehman, CEO
https://collabrity.com/ is a website operated by Collabrity Inc., a privately held Wyoming corporation. Collabrity facilitates the placement of C-Level Executives who may be contracted directly by the client, through an entity that is separate and unaffiliated with Collabrity.
Securities offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity Inc. is not a registered broker-dealer, and Finalis Securities LLC and Collabrity Inc. are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck